BGB-290

Pamiparib (BGB-290; BGB290) is an orally active, highly selective and brain penetrant PARP (IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively) inhibitor with potent anti-tumor activity.


Cat. No.: EX-A2869	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	600	In-stock
250mg	1050	In-stock
1g	2850	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Pamiparib
CAS No.	1446261-44-4
Purity	>98%
Formula	C16H15FN4O
Mol Weight	298.3149
Appearance	white to off-white powder
Solubility	Soluble in DMSO(>50mg/mL)
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Changyou Zhou, et al. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. WO 2013097225 A1. [2]. Friedlander M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20(9):1306-1315.
CoA	CoA of BGB-290

Smiles:	C[C@]12CCCN1CC1=NNC(=O)C3=CC(F)=CC4=C3C1=C2N4


		Search